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ABSTRACT
Obesity and metabolic syndrome are associated with several cancers, however, 
the molecular mechanisms remain to be fully elucidated. Recent studies suggest 
that hypercholesterolemia increases intratumoral androgen signaling in prostate 
cancer, but it is unclear whether androgen-independent mechanisms also exist. Since 
hypercholesterolemia is associated with advanced, castrate-resistant prostate cancer, 
in this study, we aimed to determine whether and how hypercholesterolemia affects 
prostate cancer progression in the absence of androgen signaling. We demonstrate 
that diet-induced hypercholesterolemia promotes orthotopic xenograft PC-3 cell 
metastasis, concomitant with elevated expression of caveolin-1 and IQGAP1 in 
xenograft tumor tissues. In vitro cholesterol treatment of PC-3 cells stimulated 
migration and increased IQGAP1 and caveolin-1 protein level and localization to a 
detergent-resistant fraction. Down-regulation of caveolin-1 or IQGAP1 in PC-3 cells 
reduced migration and invasion in vitro, and hypercholesterolemia-induced metastasis 
in vivo. Double knock-down of caveolin-1 and IQGAP1 showed no additive effect, 
suggesting that caveolin-1 and IQGAP1 act via the same pathway. Taken together, 
our data show that hypercholesterolemia promotes prostate cancer metastasis 
independent of the androgen pathway, in part by increasing IQGAP1 and caveolin-1. 
These results have broader implications for managing metastasis of cancers in general 
as IQGAP1 and hypercholesterolemia are implicated in the progression of several 
cancers.
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INTRODUCTION
Epidemiological studies have long reported an 
association between hypercholesterolemia, obesity and 
several types of cancers, with cholesterol-lowering 
drugs showing clinical benefit in the prevention and 
delay of prostate cancer progression [1, 2]. Recent 
studies have begun to reveal the potential mechanisms 
by which the cholesterol biosynthetic pathway and its 
metabolites impact carcinogenesis [3-6]. Elevated blood 
cholesterol levels may enhance the androgen receptor 
pathway via intratumoral de novo androgen synthesis in 
the prostate, contributing to prostate cancer progression 
[7]. The cholesterol metabolite 27-hydroxycholesterol 
increases estrogen receptor function in breast cancer [4, 
5], while oxidized cholesterol metabolites (oxysterols) 
released from tumor cells promote angiogenesis and 
immunosuppression in the tumor microenvironment [8]. 
In addition to its role in steroid hormone synthesis 
and function, cholesterol is an essential structural 
component of mammalian membranes. Cholesterol-
enriched membrane microdomains, also termed lipid 
rafts, are reported to regulate a myriad of cellular 
functions [9]. Previous studies suggest a potential role 
for membrane cholesterol [10]. and the cholesterol-
binding membrane protein, caveolin-1, in promoting 
prostate cancer progression [11]. Elevation of lipid 
profiles, including cholesterol, is a common side effect 
of androgen deprivation therapy for advanced prostate 
cancer [12]. Given the association of hypercholesterolemia 
with advanced, castrate-resistant prostate cancer which 
is insensitive to androgen pathway blockade [13], it is 
important to determine whether high circulating and 
cellular cholesterol can directly affect advanced prostate 
cancer progression in the absence of androgen signaling.
In this study, we examined the effects of diet-
induced hypercholesterolemia on androgen-receptor 
negative prostate cancer progression, and investigated 
the potential mechanisms. We show that diet-induced 
hypercholesterolemia accelerated secondary tumor 
metastases to lymph node, lung and bones in orthotopic 
xenograft mice using androgen receptor negative PC-3 
cells. Ras GTPase-activating-like protein IQGAP1 was 
identified and validated as a hypercholesterolemia-
induced metastasis-associated protein. Moreover, we show 
that knockdown of IQGAP1 or caveolin-1 in PC-3 cells 
abolished the hypercholesterolemia-induced metastasis 
from xenografts, indicative of their functional involvement 
in prostate cancer metastasis in vivo. IQGAP1 is a 
membrane-cytoskeleton scaffolding protein implicated in 
the progression of several types of tumors, potentially by 
regulating the Ras-MAP kinase and rac-cdc42 pathways 
[14-16]. Recruitment of IQGAP1 to plasma membrane 
ruffles facilitates cell migration [15], however, a role for 
cholesterol-enriched membranes in IQGAP1 regulation 
has not been examined. 
RESULTS
Diet-induced hypercholesterolemia accelerates 
xenografted tumor metastasis
To determine the direct but androgen-independent 
effects of hypercholesterolemia on advanced prostate 
cancer progression, we used an androgen-receptor 
negative prostate cancer cell line PC-3, expressing 
the luciferase gene (Supplementary Figure S1) in an 
orthotopic xenograft mouse model. Male NOD/SCID mice 
were randomly assigned to low-cholesterol normal (LC-D) 
and isocaloric hypercholesterolemic diet (HC-D) groups. 
Two weeks after diet initiation, in vivo and ex vivo studies 
were performed as illustrated in Figure 1a. Similar to 
previous studies [7, 10], serum cholesterol levels (Figure 
1b) but not body weights (Figure 1c) were significantly 
increased in the HC-D group. However, the intensity of 
in vivo bioluminescence (p = 0.87, Figure 1d and 1e) and 
final prostate tumor weights (p = 0.23, Figure 1f) were 
not significantly different between the groups, although 
the HC-D group showed an increased trend.
Ex vivo bioluminescence imaging was used to assess 
metastasis from the xenograft tumors [17]. Previous studies 
have reported PC-3 metastases including microscopic lung 
and bone metastases [18, 19]. The HC-D group showed 
higher bioluminescence intensity in the para-aortic lymph 
node (p = 0.0007, Figure 1g), mesenteric lymph node (p 
= 0.0021, Figure 1h) and the lung (p = 0.0275, Figure 
1i). Bone metastasis is the major cause of prostate cancer 
related death [20] and previous studies have reported 
microscopic bone metastases from PC-3 xenograft tumors 
[18]. Indeed, 42% of bones collected from the LC-D 
group showed ex vivo positive bioluminescence (Figure 
1j). Consistent with lymph node and lung metastases, 
an increased number of bones demonstrated positive 
bioluminescence in mice in the HC-D group in both the 
front (p = 0.0036) and rear legs (p = 0.0014, Figure 1j). 
Lymph node metastases and microscopic metastases 
of lung and bone marrow as well as metastasis in joint 
tissues were confirmed by histopathology (Supplementary 
Figure S2). Taken together, these results demonstrate that 
diet-induced hypercholesterolemia increased PC-3 tumor 
metastasis but not primary tumor growth.
Diet-induced hypercholesterolemia is associated 
with increased IQGAP1 and caveolin-1 in the 
tumor
Metastatic prostate cancer is one of the most 
common causes of cancer-related death in men [21]. 
To identify the molecular mechanism which mediates 
hypercholesterolemia-stimulated prostate cancer 
metastasis, we first evaluated angiogenesis and hormone 
Oncotarget3www.impactjournals.com/oncotarget
receptor signaling, based on recent reports [3-6, 8, 22]. 
Tumor angiogenesis and lymphangiogenesis were 
examined by staining primary tumor sections with 
the panendothelial cell marker endomucin and the 
lymphatic specific marker podoplanin (Figure 2a). No 
significant difference in angiogenesis (Figure 2a and 2b) 
or lymphangiogenesis (Figure 2a and 2c) was observed. 
While PC-3 cells lack androgen receptor expression, it was 
possible that hypercholesterolemia increased circulating 
testosterone levels which could positively affect tumor 
stroma tissues. Hence we measured serum testosterone 
levels (Figure 2d). Surprisingly, serum testosterone levels 
were significantly decreased in both diet groups at the 
conclusion of the experiment (p = 0.016 in LC-D and 
p < 0.0001 in HC-D, Figure 2d) which might be due to 
aggressive invading tumor cells from the primary and 
secondary tumors to the testis and surrounding organs/
tissues (Figure 2e and Supplementary Figure S3). 
Additionally, hypercholesterolemia was associated with 
a greater reduction in circulating testosterone levels, 
Figure 1: Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis but not 
primary tumor growth. (a) Experimental plan. Fourteen days prior to xenografting, male NOD/SCID mice were randomly allocated 
to low-cholesterol normal diet (LC-D, n = 14) or to a hypercholesterolemic diet (HC-D, n = 15). On day 0, human prostate cancer PC-3 
expressing the luciferase gene were orthotopically injected into the dorsolateral prostate glands. (b) Serum cholesterol, (c) body weight 
and (d and e) primary tumor growth was measured by in vivo bioluminescence imaging on the indicated days during the course of the 
experiment. (f) At the end of the experiment, primary prostate tumors were weighed after removing seminal vesicles and the urinary bladder. 
Ex vivo imaging was used to measure metastasis in (g) para-aortic lymph node (P-LN), (h) mesenteric lymph node (M-LN), (i) lung, and 
(j) bone. Error bars show standard error of the mean. NS, not significant; *p < 0.05; **p < 0.005; ***p < 0.0005. Group comparison in (j) 
used Fisher’s exact test, **p < 0.005.
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possibly due to negative feedback in impaired testicular 
functions [23, 24].
To identify metastasis-promoting proteins induced 
by cholesterol, we performed in vitro quantitative 
proteomics using stable isotope labeling by amino acids 
in cell culture (SILAC). Initial experiments showed that 
long-term growth of cell culture in reduced-cholesterol 
media affected cell proliferation, anchorage-independent 
growth, as well as migration (Supplementary Figure S4). 
To mimic the in vivo results of increased metastasis but not 
primary tumor growth, we selected a short-term, 5 hour 
treatment which increased PC-3 transmigration (Figure 
3a) but not proliferation (Figure 3b). Therefore, SILAC 
was performed according to the scheme in Figure 3c.
Compared to cells maintained in cholesterol-
deficient medium (CDM) containing 5% delipidated fetal 
bovine serum (FBS), incubation with additional 5 µM 
cholesterol for 5 hours significantly altered total cellular 
cholesterol level (Figure 3d) but not total cellular protein 
amount (Figure 3e). Liquid chromatography-tandem 
mass spectrometry and database searching identified 
and quantified a total of 441 proteins from 3 biological 
replicates. Significance of SILAC ratios was determined 
by permutation test [25-27]. By applying a 1.5 fold 
change filter for biological significance, 31 proteins 
were deemed to be significantly altered by cholesterol 
supplementation (Figure 3f and, Supplementary Table S1 
and S2). The top ten proteins up-regulated by short-term 
cholesterol treatment included Ras GTPase-activating-
like protein IQGAP1 (Figure 3g), a protein implicated 
in tumor metastasis in several cancers [16]. IQGAP1 
is a scaffolding protein which interacts with Rac1 and 
Cdc42, promoting actin polymerization at the leading 
edge of migrating cells [28]. As there are no reports 
linking hypercholesterolemia or prostate cancer with 
IQGAP1, we went on to confirm this result in vitro and 
in vivo. In parallel with IQGAP1, we also measured the 
level of caveolin-1 as it is associated with metastasis and 
poor prognosis in prostate cancer [19, 29] and has been 
functionally linked with IQGAP1[30-32].
We performed Western blotting of both xenograft 
tumor and cell lysates to determine the effect of 
hypercholesterolemia on the expression of level of 
caveolin-1 and IQGAP1. Interestingly, xenograft tumor 
lysates from the HC-D group showed higher expression of 
both IQGAP1 (2.85 ± 0.50, p = 0.003) and caveolin-1 (3.0 
± 0.7, p = 0.011, Figure 3h), although cholesterol treatment 
of PC-3 cells in vitro increased expression of IQGAP1 but 
not caveolin-1 (Figure 3i). Cholesterol elevation in the 
tumor was confirmed (Figure 3j). The differences between 
Figure 2: Diet-induced hypercholesterolemia is not associated with increased angiogenesis, lymphangiogenesis, and 
circulating testosterone levels. (a) Representative images show double immunofluorescence staining of tumor tissue sections using 
the panendothelial cell marker endomucin (red) and the lymphatic specific marker podoplanin (green). Bar, 200 μm. (b) Angiogenesis was 
not significantly different between hypercholesterolemic and control diet groups (p = 0.3297, n = 9 per group). (c) Immunostaining for 
lymphangiogenesis demonstrated no significant difference between the diet groups (p = 0.35, n = 9 per group). (d) Circulating testosterone 
level was measured at days 0 and 42 using a homogeneous time resolved fluorescence assay. Data were represented as mean ± SEM (**p 
< 0.005, ***p < 0.0005). (e) Histopathology using H&E tissue sections demonstrated tumor cells invading into the capsule of the testes 
(arrows, tumors). Bar, 100 μm.
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in vivo and in vitro data may relate to the different duration 
of hypercholesterolemia, presence of stromal cells, tissue 
architecture and/or feedback mechanisms in vivo.
Cholesterol and caveolin-1 recruit IQGAP1 to 
lipid organized membrane microdomains
Having established IQGAP1 as a cholesterol-
induced protein in PC-3 cells, we next examined its 
expression in other commonly-used prostate cancer cell 
lines (Figure 4a). In agreement with a role in mediating 
metastasis, the level of IQGAP1 is higher in aggressive 
prostate cancer cells, PC-3 and DU145, which also express 
caveolin-1 (Figure 4a). Compared to PC-3 cells (Figure 
3i), caveolin-1-negative LNCaP cells showed a delay in 
time-response of cholesterol-induced IQGAP1 elevation, 
which was significant at 20 hours but not at 5 hours post 
cholesterol addition (Supplementary Figure S5). These 
results suggest an association between cholesterol-
sensitivity and aggressiveness of prostate cancer cell lines, 
with IQGAP1 being a potential downstream effector.
Cholesterol regulates gene expression via two 
transcription factors, sterol regulatory element binding 
protein (SREBP) and liver X receptor (LXR). Hence, we 
tested the hypothesis that hypercholesterolemia increases 
IQGAP1 protein at the transcriptional level using qPCR. 
Surprisingly, IQGAP1 mRNA was not responsive to 
cholesterol or oxysterol treatment in PC-3 and LNCaP 
cells (Figure 4b and Supplementary Figure S6), indicating 
that hypercholesterolemia increases IQGAP1 protein at a 
post-transcriptional level.
Next, we investigated if hypercholesterolemia 
altered membrane localization of IQGAP1, which 
mediates cell migration [15]. Dynamic membrane re-
organization occurs during cell migration and is regulated 
by caveolin-1 via cholesterol-rich membranes (also called 
lipid rafts), partly through its role as the structural protein 
of plasma membrane pits caveolae [1, 30]. While IQGAP1 
is known to be enriched in membrane ruffles, association 
with cholesterol-rich membranes has not been examined. 
We evaluated the effect of cholesterol treatment on the 
Figure 3: In vitro quantitative proteomics suggests IQGAP1 as a cholesterol-related candidate. (a) PC-3 transmigration 
assay was performed using cholesterol-deficient medium (CDM) or control FBS (Ctrl-FBS). (b) PC-3 proliferation was determined using 
Alamar Blue assay. (c) Experimental plan for in vitro quantitative proteomics study using stable isotope labeling by amino acids in cell 
culture (SILAC). (d) Total cellular cholesterol and (e) protein concentrations of whole cell lysates were measured. (f) Cholesterol treatment 
(5 μM for 5 hours) significantly altered 41 out of 441 proteins, based on a 1.5 fold difference and p-values less than 0.05. (g) Top 10 
protein candidates up-regulated by cholesterol treatment. Uniprot, UniProt Entry ID; Name, gene name; Ratio ± STD, cholesterol(heavy)/
control(light) SILAC ratio ± standard deviation; Adj. p-value, permutation p-value adjusted for multiple testing. (h) Immunoblotting of 
tumor lysates show that expression levels of IQGAP1 and caveolin-1 were significantly increased in HC-D group (n = 9 per group). (i) 
PC-3 cells were incubated with 5 μM cholesterol or vehicle for 5 hours. Total cell lysates (20 μg) were separated on SDS-PAGE and 
immunoblotted with antibodies against IQGAP1, caveolin-1 and β-actin as indicated. IQGAP1 but not caveolin-1 was significantly altered 
by short-term cholesterol treatment. (j) Intratumoral cholesterol levels was measured in tumor lysates using Amplex Red cholesterol assay 
(n = 9 per group). Error bars show standard error of the mean; NS, not significant ; *p < 0.05; **p < 0.005.
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Figure 4: Cholesterol regulates IQGAP1 targeting to detergent-resistant fractions. (a) Relative expression of IQGAP1 and 
caveolin-1 in prostate cancer cell lines. Total cell lysates (20 μg) from PC-3, LNCaP, 22Rv1 and DU145 were resolved on SDS-PAGE 
and immunoblotted for IQGAP1 and caveolin-1. Loading control: Coomassie staining. (b) Cholesterol treatment for 5 hours does not 
alter caveolin-1 or IQGAP1 transcription as measured by qRT-PCR. (c) Immunofluorescence labeling for IQGAP1 (red) and staining for 
cholesterol using Filipin III (blue) in PC-3 cells, after treatment with 5 μM cholesterol or vehicle for 20 hours. Arrows, membrane ruffles 
enriched in cholesterol and IQGAP1. Bars, 10 μm. (d) IQGAP1 levels in detergent-resistant fractions (DRF) was examined in PC-3 cells 
(n = 3). (e) Immunofluorescence co-labeling for caveolin-1 and IQGAP1 in PC-3 cells after 20 hour treatment with 5 μM cholesterol or 
vehicle. Bars, 10 μm. (f) DRF was collected from equal numbers of caveolin-1 knockdown (shCav1) and control scrambled sequence 
knockdown (Scr) PC-3 cells. Equivalent volumes of DRF were separated by SDS-PAGE and immunoblotted for IQGAP1, flotillin-1 or 
caveolin-1. n = 3. Error bars show standard error of the mean; NS, not significant; *p < 0.05. Veh, vehicle; Chol, cholesterol.
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localization of IQGAP1 in PC-3 cells (Figure 4c). IQGAP1 
showed diffuse and punctate staining in control cells. After 
20 hour treatment in cholesterol, we observed increasing 
localization of IQGAP1 to membrane ruffles (Figure 4c, 
arrows) which also stained with filipin, an antibiotic which 
stains cholesterol. These results suggest that cholesterol 
induced the translocation of IQGAP1 to cholesterol-
rich membranes in the ruffles. To further investigate 
this, we employed a biochemical method of preparing 
cholesterol-rich membranes, previously established as 
detergent resistant fractions (DRFs) [33]. Caveolin-1 is a 
known membrane cholesterol-binding protein and served 
as a positive control for the fractionation. IQGAP1 was 
detected in PC-3 DRF (Figure 4d). Both caveolin-1 and 
IQGAP1 levels in DRF were increased by cholesterol 
treatment (Figure 4d). 
Previous studies suggest a functional interaction 
between caveolin-1 and IQGAP1 in regulating the ERK 
[31] and integrin-linked kinase signaling pathways [32]. 
Our results show that hypercholesterolemia increases 
the level of both proteins in the DRF fraction, but it is 
not clear whether caveolin-1 and IQGAP1 actually co-
localize to the same membranes. To address this question, 
we performed immunofluorescence co-localization with 
and without cholesterol treatment (Figure 4e). Some co-
localization was observed, but the effect of a 20 hour 
cholesterol treatment was minor (mean Pearson’s R-values 
of 0.35 and 0.36 for control and cholesterol, respectively). 
In view of the previous publications on the functional 
interaction between caveolin-1 and IQGAP1 [31, 32], we 
also investigated if caveolin-1 is required for recruitment 
of IQGAP1 to DRF (Figure 4f). Interestingly, we observed 
a reduced level of DRF IQGAP1 in shCav1 PC-3 cells, 
while another cholesterol-rich membrane microdomain-
associated protein, flotillin-1, was not affected (Figure 
4f). These results suggest that caveolin-1 indirectly 
regulates IQGAP1-membrane association, potentially by 
modulating membrane lipid organization [34].
IQGAP1 and caveolin-1 facilitate PC-3 metastasis
To further evaluate the involvement of IQGAP1 
and caveolin-1 in PC-3 metastases in vivo, we performed 
hypercholesterolemic diet xenograft experiments 
using PC-3-luc cell lines with reduced IQGAP1 and/
or caveolin-1 expression. Firstly, pooled populations of 
shIQGAP1 and shCav1 PC-3 cells were established using 
lentiviral mediated shRNAs and flow cytometry (based on 
the bicistronic co-expression of GFP in the lentivirus). A 
double knockdown cell line was generated by infecting 
shIQGAP1 cells with shCav1 lentivirus. Reduced protein 
levels were confirmed by Western blotting (Figure 5a). 
Preliminary in vitro studies showed similar attenuation of 
transmigration and invasion between shIQGAP1, shCav1 
and double knockdown cells compared to scrambled 
control (Figure 5b, 5c and Supplementary Figure S7). 
There was no difference in proliferation between the 4 
Figure 5: Knockdown of IQGAP1 and/or caveolin-1 in PC-3 cells reduces migration and invasion in vitro. PC-3-luciferase 
cell lines with reduced expression of IQGAP1 (shIQGAP1), caveolin-1 (shCav1) and both (shIQ+shCav) were generated using lentiviral-
mediated shRNA. (a) Relative protein expression of IQGAP1 and caveolin-1 was measured by immunoblotting and quantified over 3 
experiments. (b) Transmigration, (c) Matrigel invasion and (d) proliferation assays were performed for PC-3 stable cell lines. Error bars 
show standard error of the mean. **p < 0.005, ***p < 0.0005. Additional shRNAs produced similar phenotypes (Supplementary Figure S7).
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cell lines (Figure 5d). Before performing in vivo study, 
the intensity and linearity of in vitro bioluminescence of 
PC-3-luc shIQGAP1 and shCav1 cell lines were confirmed 
for accurate comparison between groups (Supplementary 
Figure S8). 
A total of 42 male NOD/SCID mice were randomly 
assigned to and xenografted with scrambled control (Scr-
Ctrl), IQGAP1 knockdown (shIQGAP1), caveolin-1 
knockdown (shCav1) and double knockdown (shIQ+shCa) 
PC-3 cells. In vivo and ex vivo studies were performed 
as described in Figure 1a using HC-D. As expected, 
all groups showed similar body weight (p = 0.21, 
Supplementary Figure S9a) and serum cholesterol levels 
(p = 0.96, Supplementary Figure S9b). Whole body in vivo 
imaging showed similar primary tumor growth curves (p 
= 0.55, Figure 6a and 6b), and final prostate tumor weight 
also revealed no significant changes (p = 0.39, Figure 6c) 
between the groups. Tumor metastases were determined 
in lymph nodes, lung and bones including joint tissues. 
Measurement of lymph node size revealed significantly 
smaller lymph nodes in knockdown groups compared to 
control (p < 0.0005), but not among knockdown groups 
(p = 0.8809, Figure 6d). Similarly, ex vivo imaging 
demonstrated significantly reduced lymph node metastases 
(Figure 6e and 6f) as well as microscopic lung metastases 
(Figure 6e and 6g). Pairwise comparisons using Fisher’s 
exact test also demonstrated significantly reduced 
metastatic invasion to the bones and joints in shIQGAP1 
(front limbs; p = 0.0003, rear limbs; p = 0.0005), shCav1 
(p = 0.012 and p = 0.0023, respectively), or double 
knockdown PC-3 cells (p = 0.0095 and p = 0.0012, 
respectively, Figure 6h). Double knockdown of IQGAP1 
and caveolin-1 showed no additive effects in the reduction 
of metastases (Figure 6f, 6g and 6h) suggesting action 
via the same molecular pathway. Taken together, these 
results suggest that IQGAP1 and caveolin-1 potentiate 
PC-3 metastasis, and that the elevation of IQGAP1 
levels in hypercholesterolemia plays an important role in 
metastasis.
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Figure 6: Knockdown of IQGAP1 and/or caveolin-1 suppressed hypercholesterolemia-induced prostate cancer 
metastasis. In vivo metastasis was assayed for shIQGAP1, shCav1 and shIQ+shCav1 PC-3-luciferase cells in HC-D intraprostatic 
xenograft model. (a and b) Real-time xenografted primary prostate tumor growth was monitored using whole body in vivo bioluminescence. 
Scrambled control (Scr-Ctrl, n = 10), IQGAP1 knockdown (shIQGAP1, n = 11), caveolin-1 knockdown (shCav1, n = 11), and double 
knockdown of IQGAP1 and caveolin-1 (shIQ+shCav1, n = 10). (c) Final prostate tumor weight was assessed after removing seminal 
vesicles and urinary bladder. Representative figures are shown (Bar, 10 mm). (d) The size of para-aortic lymph nodes was measured. 
(e) Representative figures show ex vivo bioluminescence imaging for para-aortic lymph nodes (P-LN) and the lung tissues. Ex vivo 
bioluminescence was measured for secondary metastases in (f) para-aortic lymph nodes, (g) lung and (h) bone. Error bars show standard 
error of the mean. NS, not significant; *p < 0.05, **p < 0.005, ***p < 0.0005.
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DISCUSSION
Androgen-deprivation therapy is the first line of 
treatment for advance prostate cancer. While highly 
effective in androgen-sensitive disease, resistance 
ultimately develops in most patients [13]. Androgen-
deprivation therapy is associated with a spectrum of side 
effects, including elevated circulating cholesterol [12] 
which may paradoxically promote androgen-independent 
prostate cancer metastasis based on this study using 
a xenograft mouse model. Our results indicate that 
in addition to the recently reported hormone receptor 
and cholesterol metabolism dependent mechanisms [3, 
7] hypercholesterolemia per se can increase prostate 
cancer metastasis by modulating the properties of 
membrane microdomains. We further demonstrate the 
involvement of two proteins, caveolin-1 and IQGAP1 in 
hypercholesterolemia-induced xenograft tumor metastasis 
in vivo. Hence, caveolin-1, IQGAP1, or cholesterol-
rich membrane microdomains (lipid rafts) are potential 
therapeutic targets for prevention or treatment of tumor 
metastasis.
Caveolin-1 is a cholesterol binding protein well 
characterized by its role in formation of plasma membrane 
pits, caveolae [30]. Caveolin-1 has been considered a 
biomarker and therapeutic target in prostate cancer as it 
is released from prostate cancer cells, can be detected in 
the serum and positively associates with prostate cancer 
grade [29, 35, 36]. However, caveolin-1 plays complex 
roles in cancer, with no existing models to explain its 
apparent contradictory tumor promoter and suppressor 
roles. Recent studies have begun to reveal the complexity 
of caveolin-1 function in cancer. Firstly, caveolin-1 
may function pathologically outside caveolae via non-
caveolar caveolin-1 membrane raft domain (caveolin-1 
microdomains), as discovered in PC-3 cells [37] and 
validated in prostate cancer tissue samples [19]. While 
caveolin-1 microdomains (not caveolae) are aberrantly 
induced in advanced prostate cancer cells, caveolae is 
reduced in the stroma during prostate cancer progression 
[19]. Given the complexity of caveolin-1 cellular and 
subcellular expression during cancer progression, 
therapeutic targeting of caveolin-1 is challenging. 
Furthermore, the molecular mechanisms of caveolin-1 
in cancer progression have not been fully elucidated, 
although it likely involves modulation of lipid rafts and, 
based on the present data, IQGAP1.
IQGAP1 is a ubiquitously expressed scaffolding 
protein that co-ordinates spatial signaling to regulate 
mitogenic, morphological and migratory processes [14]. 
Recent studies implicate a role for IQGAP1 in cancer, 
with overexpression reported in ovarian [38], liver [39], 
advanced colorectal [40], thyroid [41], pancreatic cancer 
[42] and squamous cell carcinoma [16]. Consistent with 
the known ubiquitous expression of IQGAP1, we detected 
it in all 4 commonly used prostate cancer cell lines (Figure 
4a). Interestingly, IQGAP1 expression level correlated 
with aggressiveness of the cell lines, and shows correlation 
with caveolin-1, a known regulator of cholesterol 
membrane microdomains (Figure 4a). Furthermore, loss 
of caveolin-1 expression attenuated the level of IQGAP1 
in the detergent resistant fraction (Figure 4f), indicative 
of caveolin-1-dependent recruitment to cholesterol-
rich membrane domains. While IQGAP1 membrane 
targeting is essential for its regulation of migration, to our 
knowledge, this is the first report of IQGAP1 targeting 
to cholesterol-rich membrane microdomains. Since 
cholesterol is essential for all cell types, and IQGAP1 is 
ubiquitously expressed, we asked if IQGAP1 targeting 
to cholesterol-rich lipid rafts can be detected in other 
cancer cells. By scrutinizing 66 mass spectrometry-based 
human lipid raft proteomics studies published between 
2001 and 2013 using RaftProt database [43], we found 
that IQGAP1 was identified in 12 experiments which 
included 5 cancer cell lines, namely HeLa cervical 
cancer, SW620 and SW480 colorectal cancer, NG108-
15 neuroblastoma-glioma hybrid, and Jurkat acute T cell 
leukemia [44-48]. Both detergent-based and detergent-
free lipid raft extraction methods were featured in these 
experiments, indicating that the presence of IQGAP1 
was not an isolation artifact. Furthermore, sensitivity to 
the cholesterol-depleting agent methyl-β-cyclodextrin 
suggests that IQGAP1 is a bona fide lipid raft protein.
[48] Interestingly, lipid raft IQGAP1 level was elevated 
in a metastatic colorectal cancer cell line, compared to 
a non-metastatic cell line derived from the same patient 
[45]. On the other hand, CCL20 and cisplatin treatment 
did not affect lipid raft IQGAP1 levels in Jurkat cells 
[46, 47]. Taken together, these data add support to our 
experimental results showing that IQGAP1 targeting to 
lipid raft membranes can be regulated and may contribute 
to cancer metastasis.
In addition to IQGAP1, it is likely that other 
cholesterol-rich membrane microdomain-associated 
proteins are altered by hypercholesterolemia to impact on 
tumor metastasis. Some examples include CD44, ezrin, 
uPAR and MMP-9 [49, 50]. This study adds alteration of 
cholesterol-rich microdomain composition and function to 
the increasing battery of molecular mechanisms linking 
hypercholesterolemia and cancer development and 
progression. Our results also highlight the importance 
of monitoring and maintaining low to normal blood 
cholesterol levels for prostate cancer patients, particularly 
those undergoing androgen deprivation therapy which can 
elevate cholesterol [12].
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MATERIALS AND METHODS
Cell lines
Human prostate cancer cell lines PC-3 and LNCaP 
were purchased from American Type Culture Collection 
(ATCC). Human prostate cancer cell lines DU145, and 
PC-3 cells stably expressing firefly luciferase genes[51] 
were kindly provided by Dr. Ming-Tat Ling (Australian 
Prostate Cancer Research Centre–Queensland and 
Institute for Biomedical Health & Innovation, Queensland 
University of Technology, Translational Research Institute, 
Brisbane, Australia). The prostate cancer cell line 22Rv1 
was kindly provided by Dr. John Hooper (Mater Medical 
Research Institute, Translational Research Institute, 
Brisbane, Australia). Prostate cancer cell lines were grown 
in RPMI-1640 medium (Invitrogen) supplemented with 
5% fetal bovine serum (FBS).
Reagents
Xenolight D-luciferin potassium salt was obtained 
from ThermoFisher. Standard (low-cholesterol) control 
diet and hypercholesterolemic diet (SF12-007, equivalent 
to TD88051, Harlan[10]) were purchased from Specialty 
Feeds (Glen Forrest, WA, Australia). Cholesterol levels 
were measured using Amplex Red cholesterol Assay 
Kit (Invitrogen), and fluorescence was measured by 
FLUOstar OPTIMA (BMG Labtech). Serum testosterone 
level was measured using homogeneous time resolved 
fluorescence based total testosterone assay kit (Cisbio) 
with a microplate reader, Artemis 101 (Cosmo Bio). 
Anti-caveolin-1 (610407) and anti-flotillin-1 (610821) 
antibodies were from BD Transduction Laboratories, anti-
IQGAP1 (22167-1-AP) from ProteinTech, anti-β-actin 
(A1978) from Sigma, anti-endomucin (sc-53941) from 
Santa Cruz Biotechnology and anti-podoplanin (RDI-
103M40X) from Bioclone Aust. Alexa-fluor secondary 
antibodies were from Invitrogen. 
Orthotopic prostate cancer xenograft and 
monitoring mice
Use of mice and all animal experiments described 
in this paper were conducted after prior approval by the 
University of Queensland Animal Ethics Committee 
(UQDI/326/10/AICR). Seven-week-old male NOD/SCID 
mice were purchased from the Animal Resource Centre 
(Canning Vale, WA, Australia), housed and maintained at 
the University of Queensland Biological Resource Animal 
Facility.
All animal experiments including in vivo and ex 
vivo imaging were performed by two veterinarians as 
previously described [19]. Prior to xenograft experiments, 
the in vitro bioluminescence (BLI) sensitivity and 
linearity of PC-3-luciferase cell lines were confirmed 
(Supplementary Figures S1 and S8). Briefly, 2.5 x 105 
PC-3-luciferase cells were orthotopically injected into 
the dorsolateral prostate glands of male NOD/SCID 
mice under a dissecting microscope. Prior to in vivo 
bioluminescence imaging, D-luciferin dissolved in 
PBS was intraperitoneally injected, and then mice were 
anesthetized under isoflurane. At the end of the final 
experiments, mice were euthanized, and organs were 
collected in small 6 to 10 cm dishes containing PBS for 
ex vivo imaging. All ex vivo imaging was finished within 
15 minutes. The size of lymph nodes was measured using 
a caliper [tumor volume = (width)2 x length/2]. Mouse 
tissues were fixed in 10% neutral-buffered formalin for 
24 hours, and bone tissues were decalcified in 10% EDTA 
for more than 2 weeks. Histopathological changes in 
mouse tissues were carefully examined by a veterinary 
pathologist. In order to examine serum cholesterol and 
testosterone levels, retro-orbital sinus bleeding and cardiac 
puncture were used after diet restriction for 2 hours.
Angiogenesis and lymphangiogenesis
Paraffin-embedded sections were used for staining 
with the panendothelial cell marker endomucin and the 
lymphatic specific marker podoplanin. The staining 
and quantification of the lymphatic and blood vessel 
densities for 5 randomly selected fields for each slide was 
performed as described previously (n = 9 per each) [52]. 
Nuclei were stained using 4’,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI). Slides were mounted on 
coverslips with 70% glycerol in PBS solution.
Cholesterol-deficient medium and cholesterol 
loading in vitro
To modulate cellular cholesterol levels in vitro, 
delipidated FBS and dialyzed FBS (control FBS) were 
used. Delipidated FBS was prepared by extracting lipids 
from FBS using diisopropylether and n-butanol in a 
ratio of 2:1. After centrifugation at 350 g for 15 minutes 
at 4°C, the supernatant was removed. FBS re-dissolved 
in diisopropylether in 1:1 ratio was centrifuged again at 
250 g for 15 minutes at 4°C. Lastly, the supernatant was 
dialyzed against cold PBS using a 3500 MWCO dialysis 
membrane. Medium containing 5% delipidated FBS 
was used as cholesterol-deficient medium, and medium 
containing 5% dialyzed FBS without delipidation was 
used as control medium. Cholesterol (Sigma-Aldrich) 
was dissolved in ethanol, and 5 μM cholesterol or ethanol 
(vehicle) were added into cholesterol-deficient medium.
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In vitro quantitative proteomics using stable 
isotope labeling by amino acids in culture 
(SILAC)
SILAC labeling of PC-3 cells was performed as 
previously described [25], with the following amino 
acids: “0/0” cells with normal isotopic Lys and Arg and 
“4/6” cells with 2H4-Lys and 
13C6-Arg. Greater than 99% 
incorporation was confirmed for the “4/6”-labelled cells 
by liquid chromatography tandem mass spectrometry (LC-
MS/MS). 
After cholesterol treatment, cells were washed twice 
in PBS and scraped in PBS. Cell pellets were obtained 
by centrifugation at 220 g, then lysed in a modified 
RIPA buffer: 20 mM Tris pH 7.5, 150 mM NaCl, 0.5% 
Triton X-100, 0.5% sodium deoxycholate, 10 mM 
sodium fluoride, 0.5 mM sodium vanadate, 1 mM sodium 
pyrophosphate, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl 
fluoride hydrochloride and protease inhibitors containing 
1 μg/μL Aprotinin, 1 μg/μL Antipain, 1 μg/μL Pepstatin, 
1 μg/μL Leupeptin and 2.5 mM Benzamidine. Insoluble 
material was removed by pelleting at 12,000 g for 5 
minutes at 4°C. The supernatant was collected as total cell 
lysate and the protein concentration was determined using 
Bradford assay (Biorad).
In gel digest and tandem mass spectrometry
Semi-automated in-gel tryptic digestion was 
performed on a liquid handler as previously described 
[53]. Peptides were analyzed using a 1200 Series nano 
high performance liquid chromatography coupled with 
Quadrupole-Time of Flight 6520 with a Chip-Cube 
interface (Agilent Technologies) as described [53]. 
Spectrum Mill (Agilent, B.04.00.127) was used for data 
analysis. Data were extracted with carbamidomethylated 
cysteine as a fixed modification and SILAC amino acids 
N-Lys, 13C6
15N2-Lys, N-Arg and 
13C6
15N4-Arg as a mix 
modification. Extracted data were searched against the 
SwissProt (release-2011_01) human database with the 
same modifications as above, and oxidized methionine 
as a variable modification. Precursor and product mass 
tolerance was set to ± 20 ppm and ± 50 ppm respectively. 
Reverse database scores were calculated with Spectrum 
Mill search engine by using the percentage of false 
positive identifications using the following cut-off: protein 
score > 11, peptide score >10 and scored peak intensity > 
60%. All peptides identified had a global false discovery 
rate of less than 0.9%. Mean SILAC ratio (H/L) and 
standard deviations were calculated using all the peptide 
ratios matched to a protein, and p-values were calculated 
using peptide SILAC ratios as previously described [25-
27].
Immunofluorescence
Cells were grown on coverslips and fixed in 4% 
paraformaldehyde for 30min followed by three washes 
in PBS. Where stated, cells were stained with Filipin 
III (Sigma) at a concentration of 50μg/ml in PBS for 
2 hours followed by three washes in PBS. Cells were 
then permeabilized with 0.1% saponin and 5% BSA 
in PBS for 30min. Cells not stained with filipin were 
permeabilized in 0.1% Triton-X100 and 5% BSA in PBS 
for 30min, followed by 3 washes in PBS. The coverslips 
were incubated with the primary followed by secondary 
antibodies diluted in 3% BSA/PBS for 1hr each at room 
temperature. Coverslips were washed 3 times in PBS after 
the addition of each antibody. Where stated, coverslips 
were counterstained with 1μg/mL DAPI, washed three 
times with PBS, rinsed in MilliQ water and mounted 
in ProLong Diamond (Invitrogen). Cells were imaged 
by confocal microscopy (Ziess 510 Meta or Olympus 
FV1200). Pearson’s R value was calculated for 50 
individual cells in ImageJ using the Coloc2 plugin.
Generation of knockdown cell lines
In order to knockdown caveolin-1 and/or 
IQGAP1 expression, lentiviral particles expressing 
shRNAs targeting IQGAP1 or caveolin-1 were 
obtained from the University of Queensland Institute 
for Molecular Bioscience, Life Science Automation 
Facility. The sequence of shRNAs for IQGAP1 was: 
shIQGAP1 (sIQ1), TGCTGTTGACAGTGAGCGATC 
CCACAAAGATGAAGTTGTATAGTGAAGCCACAGA 
TGTATACAACTTCATCTTTGTGGGAGTGCCTACTG 
CCTCGGA; shIQGAP1 (sIQ2), 
TGCTGTTGACAGTGAGCGCAAGGTTGACTTCACA 
GAAGAATAGTGAAGCCACAGATGTATTCTTCTGTG 
AAGTCAACCTTTTGCCTACTGCCTCGGA; 
shIQGAP1 (sIQ3) 
TGCTGTTGACAGTGAGCGATCGAAGGTAGATCAG 
ATTCAATAGTGAAGCCACAGATGTATTGAATCTGA 
TCTACCTTCGACTGCCTACTGCCTCGGA. 
The sequence of shCaveolin-1 was: shCaveolin-1 
(sC1), TGCTGTTGACAGTGAGCGAAACGATG 
ACGTGGTCAAGATTTAGTGAAGCCACAGATGTAA 
ATCTTGACCACGTCATCGTTGTGCCTACTGCCTCG 
GA; shCaveolin-1 (sC2), 
TGCTGTTGACAGTGAGCGCCACCACCTTCACTGT 
GACGAATAGTGAAGCCACAGATGTATTCGTCACA 
GTGAAGGTGGTGATGCCTACTGCCTCGGA; 
shCaveolin-1 (sC3), 
TGCTGTTGACAGTGAGCGACACCTTCACTGTGAC 
GAAATATAGTGAAGCCACAGATGTATATTTCGTCA 
CAGTGAAGGTGGTGCCTACTGCCTCGGA. In 
preliminary studies, these different shRNAs were tested 
(Supplementary Figure 7a) with variable results. At least 2 
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of each shRNA construct (sIQ1, sIQ3; sC1, sC2) produced 
similar functional outcomes as measured by proliferation 
and transmigration assay (Supplementary Figure 7b, 7c). 
Thereafter, sIQ3 and sC2 were selected for producing 
double knockdown cells and for in vivo experiments 
(Figure 6, and shown in Figure 5 as representative).
In vitro assays
All in vitro studies were repeated at least three 
times. PC-3 proliferation was determined using Alamar 
Blue (Invitrogen). At appropriate time points after plating 
10,000 cells in 96-well plates, cells were incubated in non-
phenol red RPMI medium containing 10% Alamar Blue 
for 3 hours at 37oC. The fluorescence was measured using 
a microplate reader, FLUOstar OPTIMA (BMG LabTech). 
Transmigration assays were performed using 8 
μm pore size transwell inserts (Corning) coated with 
collagen type I (Sigma-Aldrich) as previously described 
[54] with minor modification. Briefly 100 μl of cell 
suspension (2.5 x 106 cells per mL) in serum-free RPMI 
media containing 0.1% BSA was added into the upper 
chamber. RPMI media containing 5% FBS was added 
to the lower chamber and the PC-3 cells were allowed 
to migrate for 5 hours. The filter was rinsed in PBS and 
fixed in 4% paraformaldehyde. Cells that did not migrate 
were removed by swabbing the membrane from the top 
side of the insert. Cells remaining on the membrane were 
stained with haematoxylin. Matrigel invasion assay was 
performed similarly. Matrigel (BD Biosciences) was 
mixed 1:1 with medium, and the mixture was added into 
the transwell inserts. Then, 100 μl of cell suspension (5 x 
106 cells per mL) in serum-free RPMI media containing 
0.1% BSA was placed into the upper chamber, and then 
incubated at 37oC for 20 hours. The number of migrated 
or invaded cells was counted in 5 different fields using a 
bright field microscope.
Subcellular fractionation
A detergent-resistant lipid-rich membrane fraction 
(DRF) was prepared as previously described [33], with 
minor modification. Briefly, PC-3 (1.5 x 106) cells were 
plated in 10 cm dishes the day before harvest. Cell 
pellets were prepared by centrifugation at 220 g, and then 
homogenized in 1% Triton-X-100, 25mM Tris HCl, pH 
7.4, 150mM NaCl, 3mM EDTA and protease inhibitors 
by passage through a 27-guage needle 25 times. The 
homogenate was incubated on ice for 30 minutes, and 
then centrifuged at 16,000 g for 20 minutes at 4oC. The 
insoluble pellets (detergent-resistant fraction) were 
resuspended in 40 μl SDS-PAGE sample buffer, and 
then 10 μl samples were loaded on SDS-PAGE gels for 
Western blots. Western blots were performed as previously 
described [19].
Real-time RT-PCR
Cells were grown in triplicate on 12-well plates and 
treated as described in figure legends. Total RNA was 
harvested using TRI Reagent (Sigma-Aldrich), and reverse 
transcribed into cDNA using the SuperScript III First 
Strand cDNA Synthesis Kit (Life Technologies). mRNA 
levels were determined by qRT-PCR using SensiMix 
SYBR Green (Bioline) on a Corbett Rotorgene 3000 
(Corbett Life Sciences, Sydney, Australia) using primers 
for IQGAP1 (F: AAGAAGGCATATCAAGATCGG, R: 
CCTCAGCATTGATGAGAGTC), ABCA1 [55], HMGCR 
[56] and the housekeeping gene, porphobilinogen 
deaminase, PBGD [55]. The mRNA expression levels 
were normalized to that of PBGD and made relative to the 
vehicle condition using the ΔΔCt method.
Statistical analysis
Two-tailed statistical analysis was performed using 
the GraphPad Prism software, and p-value less than 0.05 
was regarded as significant. Pair-wise comparison for 
positive or negative bioluminescence was performed using 
Fisher’s exact test.
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